Cancer biomarker pioneer MIODx closes seed round with $1.5 Mln

MIODx, a pioneer in cancer biomarker detection, has closed its seed round with $1.5 mln. The funds will be used for the completion of the clinical utility study as well as commercialization of its oncology testing platform VerifyDx. The company has also entered into a lease to occupy 3,000 square feet at the San Jose BioCube.

9 May 2016•3 mins read
Feature image
LinkedInXEmail
LinkedInXEmail